Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 20, 2023
Grant Date -
May 21, 2020
app pub date -
Jan 21, 2020
filing date -
Jun 14, 2016
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully